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We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam
therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in
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dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin
chemotherapy.
Methods and Findings
This was a randomized, prospective clinical trial in which dogs with OSA free of gross meta-
static disease (n = 126) received carboplatin chemotherapy (4 doses) following amputation.
On study entry, dogs were randomized to receive piroxicam/cyclophosphamide with or with-
out toceranib (n = 63 each) after completing chemotherapy. Patient demographics were not
significantly different between both groups. During or immediately following carboplatin che-
motherapy, 32 dogs (n = 13 toceranib; n = 19 control) developed metastatic disease, and 13
dogs left the study due to other medical conditions or owner preference. Following carbopla-
tin chemotherapy, 81 dogs (n = 46 toceranib; n = 35 control) received the metronomic treat-
ment; 35 dogs (n = 20 toceranib; n = 15 control) developed metastatic disease during the
maintenance therapy, and 26 dogs left the study due to other medical conditions or owner
preference. Nine toceranib-treated and 11 control dogs completed the study without evi-
dence of metastatic disease 1-year following amputation. Toceranib-treated dogs experi-
enced more episodes of diarrhea, neutropenia and weight loss than control dogs, although
these toxicities were low-grade and typically resolved with supportive care. More toceranib-
treated dogs (n = 8) were removed from the study for therapy-associated adverse events
compared to control dogs (n = 1). The median DFI for control and toceranib treated dogs
was 215 and 233 days, respectively (p = 0.274); the median OS for control and toceranib
treated dogs was 242 and 318 days, respectively (p = 0.08). The one year survival rate for
control dogs was 35% compared to 38% for dogs receiving toceranib.
Conclusions
The addition of toceranib to metronomic piroxicam/cyclophosphamide therapy following
amputation and carboplatin chemotherapy did not improve median DFI, OS or the 1-year
survival rate in dogs with OSA.
Introduction
Osteosarcoma (OSA) is the most common primary bone tumor in dogs, comprising up to 85%
of all reported bone neoplasia [1]. Median survival times approach 4–5 months with amputa-
tion alone, and adjuvant chemotherapy improves median survival times to 8–12 months[2].
Despite the use of various chemotherapy protocols and novel treatment approaches, clinically
meaningful improvements in survival have not been achieved and 90% of dogs die of metastatic
disease within 2 years after treatment [3–8].
Given that most dogs with OSA possess microscopic metastatic disease at the time of pre-
sentation, a goal of therapeutic development has been to influence factors in the tumor micro-
environment that are critical for outgrowth of the metastatic tumor cells. In particular, efforts
have been directed at modulating immune responses and altering tumor access to critical ele-
ments, such as blood supply as an alternative to the standard cytotoxic approaches to treat-
ment. In veterinary medicine, metronomic chemotherapy typically consists of piroxicam and
low-dose cyclophosphamide and several publications have demonstrated modulation of both
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the tumor microenvironment and immune response with this approach [9–11]. In both veteri-
nary and human medicine, metronomic cyclophosphamide has been shown to downregulate
CD4+ Tregs [11,12]. Metronomic cyclophosphamide administered at 15 mg/m2/day has also
been associated with decreased tumor microvessel density in dogs with soft tissue sarcoma
[11]. In addition, metronomic cyclophosphamide has been shown to decrease mobilization
and viability of circulating endothelial precursors (CEPs) [13,14].
While NSAIDs are not included in most human metronomic chemotherapy protocols, pir-
oxicam has been frequently used in veterinary medicine as it has been hypothesized that COX-
2 expression in CEPs is important for their survival. As such COX-2 inhibition may decrease
the ability of CEPs to survive and proliferate in the tumor microenvironment [15]. The combi-
nation of metronomic cyclophosphamide with piroxicam in mice with canine melanoma xeno-
grafts resulted in decreased tumor microvessel density, decreased VEGF secretion and
increased TSP-1 secretion, supporting the concurrent use of metronomic chemotherapy and
NSAIDs [16].
With respect to tumor angiogenesis, vascular endothelial growth factor (VEGF) and its re-
ceptor (VEGFR) are known to play critical roles in this process. In endothelial cells activation
of the VEGFR stimulates multiple signaling pathways that promote endothelial cell survival,
increased vascular permeability and mobilization of CEPs. Tumor cells can drive the migration
of VEGFR2 expressing CEPs from the bone marrow to the tumor microenvironment through
the production of VEGF and anti-VEGF/VEGFR therapy has been shown to decrease survival
signaling and mobilization of CEPs to the site of tumor growth [17–20]. VEGF is detectable in
both human and canine OSA, and has been associated with increased malignant potential and
poor prognosis [21–25].
In human cancer therapy there are several approved inhibitors of the VEGF/VEGFR signal-
ing axis, including the small molecules sunitinib, sorafenib, and pazopanib and the monoclonal
antibody bevacizumab. While these drugs exhibit significant activity in mouse models of dis-
ease, their effects on angiogenesis and tumor progression in humans have been questionable
[26–29]. With respect to OSA, several multi-targeted VEGF inhibitors have been evaluated in
murine xenograft models of OSA and have demonstrated antitumor activity [30,31]. In addi-
tion, cediranib combined with gefitinib demonstrated antitumor activity and changes in VEGF
and VEGFR2 levels in patients with solid tumors, including one with OSA[32]. Toceranib
phosphate (toceranib; Palladia) is a multi-targeted small molecule inhibitor of several receptor
tyrosine kinases (RTKs) including VEGFR, PDGFR, KIT, and FLT-3 that was developed to be
an orally bioavailable anti-angiogenic agent [33–35]. Although toceranib was approved for the
treatment of canine mast cell tumors by virtue of its inhibition of KIT, activity against a wide
variety of tumors has been demonstrated in dogs, likely due to dysregulation of other RTKs in-
hibited by toceranib [33,36]. Previously published data demonstrate that doses of 2.4–2.75 mg/
kg of toceranib given every other day result in statistically significant increases in plasma
VEGF, a surrogate biomarker of VEGFR2 inhibition [37]. As such, the doses of toceranib cur-
rently used to treat dogs for a variety of tumors would be expected to have a similar effect.
In the setting of metastatic OSA, a retrospective study showed that approximately 48% of
dogs experienced clinical benefit (primarily consisting of stable disease) following toceranib
therapy [38]. In this study, many of the dogs were also treated with metronomic cyclophospha-
mide and/or an NSAID in conjunction with toceranib. More recently, toceranib has been
shown to downregulate levels of circulating regulatory T cells in dogs with cancer, suggesting
that some of its effects on tumors may be exerted through immunomodulation [39].
Given the potential complementary effects of metronomic chemotherapy and VEGF/
VEGFR inhibitors, they have been combined in human medicine with variable outcomes
[26,40–42]. However, in women with advanced breast cancer clinical benefit was documented
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in a substantial number of patients (63.6–68%) using combinations of bevacizumb and cyclo-
phosphamide with capecitabine or methotrexate [26,42]. These data suggest that administra-
tion of continuous low-dose metronomic chemotherapy with anti-angiogenic targeted
therapies may represent a valid strategy to address microscopic metastatic disease. Therefore,
the purpose of this clinical trial was to evaluate the impact of toceranib phosphate combined
with metronomic cyclophosphamide and piroxicam on disease free interval (DFI) and
overall survival (OS) in dogs with appendicular OSA following amputation and carboplatin
chemotherapy.
Materials and Methods
Eligibility and Ethics Statement
The Clinical Research and Advising Committee at the College of Veterinary Medicine at The
Ohio State University and the Institutional Animal Care and Use Committee (IACUC) at The
Ohio State University approved this study. IACUC approval was also obtained at the Universi-
ty of Wisconsin-Madison, North Carolina State University, Texas A&M University, University
of Minnesota, University of Missouri, University of Georgia, Colorado State University. The
private specialty practices that participated in this clinical trial do not require IACUC approval;
participation in the clinical trial was at the discretion of the Veterinary Medical Oncologist des-
ignated as principle investigator at these study sites (Hope Veterinary Specialists, Malvern, PA;
Veterinary Cancer Group, Tustin, CA,; New England Veterinary Oncology Group, Waltham,
MA; Oradell Animal Hospital, Paramus, NJ; Southeast Veterinary Oncology and Medicine, Or-
ange Park, FL; Sage Centers for Veterinary Specialty and Emergency Care, Concord, CA; VCA
Katonah Bedford Veterinary Center, Bedford Hill, NY; Southwest Veterinary Oncology, Tuc-
son, AZ; Veterinary Specialty Hospital of the Carolinas, Cary, NC; Veterinary Specialty Hospi-
tal, San Diego, CA; The Veterinary Cancer Center, Norwalk, CT). Informed consent was
obtained from all owners prior to study entry.
Dogs free of gross metastatic disease with histologically confirmed appendicular osteosarco-
ma that had undergone amputation were considered for enrollment. Only appendicular sites
involving long bones were considered for enrollment. Prior to enrollment, dogs underwent di-
agnostic tests including thoracic radiographs, complete blood count (CBC), serum biochemis-
try profile and urinalysis. Dogs were excluded if they received prior treatment with radiation
therapy or chemotherapy, or had received non-steroidal anti-inflammatory (NSAID) drugs
within 72 hours of beginning carboplatin chemotherapy.
Study Design
A total of 126 dogs with histologically confirmed appendicular osteosarcoma without evidence
of gross metastatic disease were enrolled in this study following amputation. A computer gen-
erated randomization table was established prior to study initiation and study group assign-
ment followed this table as patients were enrolled. Upon enrollment, dogs were randomized to
receive piroxicam/cyclophosphamide with or without toceranib (provided by Zoetis, Florham
Park, NJ) after completing carboplatin chemotherapy. All dogs began treatment with 4 cycles
of single agent carboplatin (300 mg/m2 IV) every three weeks within 14 days of amputation.
Prior to the fourth carboplatin treatment dogs were re-evaluated with thoracic radiographs.
Dogs without evidence of pulmonary metastatic disease began oral maintenance therapy with
piroxicam at 0.3 mg/kg PO EOD and cyclophosphamide at 10 mg/m2 PO EOD (alternating
day of dosing with toceranib) with or without toceranib at 2.75 mg/kg PO every other day
(EOD); oral therapy was initiated 3 weeks after completion of the fourth carboplatin treatment.
All dogs received 0.5 mg/kg PO famotidine every 12 hours at the start of oral maintenance
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therapy. Chlorambucil was administered at 5 mg/m2 PO EOD in place of cyclophosphamide
in the event of sterile hemorrhagic cystitis. Dogs were evaluated 2 weeks after starting oral
maintenance therapy, then once every 4 weeks thereafter for the next 8 months or until pro-
gressive disease was noted. CBC and biochemistry profile were performed every 4 weeks; uri-
nalysis was obtained every 16 weeks after starting oral maintenance therapy. Restaging with
thoracic radiographs was performed every 8 weeks.
Drug Products and Concomitant Medications
Cyclophosphamide and piroxicam were compounded by the Apothecary Shoppe (now Avella
Specialty Pharmacy, Columbus, OH) and mailed directly to owners. The Apothecary Shoppe is
certified by the Pharmacy Compounding Accreditation Board (PCAB), and was used to de-
crease the likelihood of inaccurate dosing. Chlorambucil was compounded for the 8 dogs that
developed cystitis/gastroenteritis on the cyclophosphamide by Diamondback Drugs (Phoenix
Arizona). Toceranib was provided by Pfizer Animal Heath (now Zoetis) in 10 mg, 15 mg and
50 mg size tablets.
Adverse events were recorded and graded using the VCOG-CTCAE [43]. Concomitant
medications to prevent and/or treat drug related toxicities were used at the discretion of the at-
tending clinician and included the following: antibiotics (ciprofloxacin, cefazolin, cephalexin,
amoxicillin clavulanic acid, trimethoprim-sulfamethoxazole, enrofloxacin, marbofloxacin),
anti-emetics (ondansetron, maropitant, metoclopramide), gastrointestinal protectants (omep-
razole, famotidine, sucralfate, pantoprazole, misoprostol, ranitidine), anti-diarrheal (lopera-
mide, metronidazole, Pepto-Bismol, probiotics), and pain (tramadol, gabapentin,
buprenorphine, fentanyl), proteinuria/hypertension (benazepril, enalapril), elevated liver
transaminases (Denamarin, SAMe).
Statistical Analysis
Historical control groups were taken from two previous studies of 48 and 155 dogs with osteo-
sarcoma treated with amputation and carboplatin chemotherapy to perform sample size calcu-
lations for the study. The reported 1-year survival rate in these two populations was 35% [3,7].
Assuming 80% power and 95% confidence, 47 dogs in each group were required to demon-
strate a 50% increase in the 1-year survival rate reported in the historical control population.
Due to the high attrition rate, 32 additional dogs (63 dogs total per group) were enrolled for a
total of 126 dogs. Patient characteristics were summarized by treatment group (mean ± stan-
dard deviation (SD) for continuous variables and frequency (%) for categorical variables). The
period between the date of amputation and development of detectable metastatic disease was
defined as the disease free interval (DFI). Dogs were censored from the DFI analysis if they did
not have documented metastatic disease at the time of death or last follow-up. Necropsy exami-
nation was not required, however dogs with radiographic, cytologic/histopathologic evidence
of disease progression were included in the DFI analysis. Overall survival (OS) was defined as
the time from amputation to the date of death or euthanasia. Dogs were censored from the sur-
vival analysis if they were alive at the time of last follow-up or were lost to follow-up. Kaplan-
Meier curves were used to describe DFI and OS for each group and Cox regression was used to
test for a difference in DFI or OS adjusting for characteristics found to differ by group at base-
line. OS was chosen instead of disease-specific survival to avoid under-reporting of disease-spe-
cific deaths. Plots of Schoenfeld Residuals [44,45] and tests of an interaction with time (log-
transformed) were used to determine if the proportional hazards (PH) assumption of Cox re-
gression was violated. If PH was violated, the interaction with time was retained and hazard ra-
tios were estimated at four time points: 100 days (roughly the time at which maintenance
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therapy began), time at which the hazards of the two groups converged, one time point halfway
between 100 days and time of convergence, and a final time point halfway between the time of
convergence and the maximum follow-up time. Two types of analyses were performed for DFI:
an intent-to-treat analysis and an adherence analysis. Dogs in both analyses were censored if
there was no evidence of metastatic disease. In the intent-to-treat analysis, dogs free of meta-
static disease were censored at the last known time alive without metastatic disease. For the ad-
herence analysis, dogs that left the study prior to the development of metastatic disease due to
owner preference or another medical condition were censored at the time they withdrew from
the study. The remaining dogs in the adherence analysis were censored at the last known time
without metastatic disease. An adherence analysis was not performed for OS since many pa-
tients withdrew due to medical issues that put them at a greater risk of death than patients who
remained in the study; had these patients been included in the analysis, the independent cen-
soring assumption of the Kaplan-Meier estimator and Cox regression would have been violat-
ed. Survival outcomes were also compared by tumor location (proximal humerus versus all
other locations) to assess whether location impacted outcome between treatment groups. For
adverse events that were experienced by at least five patients and at least two per treatment
group, event rates were compared across treatment groups using Poisson regression with ro-
bust standard errors estimated using Generalized Estimating Equations (GEE). Adverse events
occurring in only one treatment group were rare, and only those common enough to be com-
pared statistically were included in this analysis. Survival analyses were performed using Inter-
cooled Stata 11 (StataCorp, College Station, TX). Poisson regression was performed using
PROC GENMOD in SAS version 9.2 (SAS Inc., Cary, NC).
Results
Patient Demographics
This was a multi-institutional study, with a total of 126 dogs (63 toceranib-treated, 63 control)
enrolled from September 2010 through August 2012. Patients in the control group were heavier
and more likely to be male (Table 1). Thus, adjustments were made for patient weight and gen-
der (male, female ignoring castrated/spayed status) in the Cox regression analyses.
Dosage and Drug Modifications
The starting dose of carboplatin for all dogs was 300 mg/m2. The median dose of carboplatin
administered during the study was 300 mg/m2. Nineteen dogs had dose adjustments (range:
Table 1. Distribution of patient characteristics.
Variable Toceranib (n = 63) Control (n = 63) Total (n = 126)
Age (yrs) 8.4 ± 2.7 8.0 ± 2.6 8.2 ± 2.6
Weight (kg) 35.9 ± 10.4 40.8 ± 11.8 38.3 ± 11.3
Gender Female 0 (0%) 1 (1.6%) 1 (0.8%)
Female Spayed 36 (57.1%) 29 (46.0%) 65 (51.6%)
Male 1 (1.6%) 1 (1.6%) 2 (1.6%)
Male Castrated 26 (41.3%) 32 (50.8%) 58 (46.0%)
Breed Pure Bred 13 (20.6%) 11 (17.5%) 24 (19.1%)
Mixed Breed 50 (79.4%) 52 (82.5%) 102 (80.9%)
Tumor Location Proximal Humerus 16 (25.4%) 15 (23.8%) 31 (24.6%)
Other 47 (74.6%) 48 (76.2%) 95 (75.4%)
doi:10.1371/journal.pone.0124889.t001
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250–290 mg/m2). More than one dose adjustment occurred in 4 dogs. Carboplatin dose-delays
due to adverse events occurred in 33 dogs. The median dose of toceranib administered was
2.73 mg/kg EOD. Twenty-seven dogs had toceranib dose-reductions. In addition, temporary
toceranib discontinuation occurred in 10 dogs due to adverse events, prior to re-instituting
therapy. Drug discontinuation generally lasted 1 week. Cyclophosphamide-induced cystitis re-
sulted in 7 dogs switching from cyclophosphamide to chlorambucil at 5 mg/m2 EOD. Chlor-
ambucil was substituted for cyclophosphamide in 1 dog due to gastrointestinal adverse events.
Patient Outcome
Thirty-two dogs (25%) developed progressive disease prior to beginning oral therapy at week
14, of which 12 dogs developed metastatic lesions outside of the pulmonary parenchyma. This
is consistent with previous reports of carboplatin chemotherapy in dogs with appendicular
OSA. Thirteen dogs withdrew prior to starting oral maintenance therapy due to owner non-
compliance or other unrelated medical conditions. Of the 126 dogs entered into the study, 81
dogs (64%) received the metronomic treatment. Of the 46 dogs that received oral therapy with
toceranib, 9 dogs completed the study protocol, 20 dogs withdrew due to the development of
metastatic disease, and 17 withdrew due to owner non-compliance or other unrelated medical
conditions. Of the 35 dogs in the control group that received oral therapy without toceranib, 11
dogs completed the study protocol, 15 dogs withdrew due to the development of metastatic dis-
ease, and 9 withdrew due to owner non-compliance or other unrelated medical conditions.
The median DFI reported in the intent-to-treat analysis was 233 days for toceranib-treated
dogs and 215 days for control dogs (p = 0.274, Fig 1A, Tables 2 and 3). The median DFI re-
ported in the adherence analysis was 223 days for toceranib-treated dogs and 198 days for con-
trol dogs (p = 0.3, Fig 1B, Tables 2 and 3). The median OS was 318 days and 242 days for
toceranib-treated and control dogs, respectively (p = 0.08) (Fig 2, Tables 2 and 3). DFI was sim-
ilar across treatment groups, however there was a time-dependent difference in short-term
mortality risk (Fig 2 and Table 3). Initially, the mortality hazard was greater among control pa-
tients, but at approximately 400 days the risks converged and were not significantly different at
one year (p = 0.961) and two years (p = 0.316). The 1- and 2-year survival rates of toceranib
treated group were not significantly different from those of the control group (p = 0.963 and
0.325, respectively) (Table 2). Median DFI (182 days, p = 0.281) and OS (243 days, p = 0.28)
were shorter among patients whose cancer was located in the proximal humerus, but this dif-
ference was not significant (Table 4). In addition, proximal humeral location did not affect the
differences between treatment groups (p> 0.28 for each survival outcome).
Adverse Events
Adverse events were similar to those previously reported for carboplatin and toceranib. Grade
1 (n = 77) and 2 (n = 18) neutropenia and grade 1 thrombocytopenia (n = 26) were the most
common hematologic adverse events observed during carboplatin chemotherapy. Grade 1 di-
arrhea (n = 31), lethargy (n = 22) and vomiting (n = 18) were also commonly reported during
carboplatin administration. The primary toxicities observed during oral therapy were gastroin-
testinal and hematologic. S1 Table shows adverse event rates for all events common enough to
be modeled using Poisson regression. Patients randomized to toceranib experienced more epi-
sodes of diarrhea, neutropenia, and weight loss than patients randomized to control, although
these toxicities were low-grade and typically resolved with supportive care and dose modifica-
tions. Temporary drug discontinuation due to adverse events was usually 1 week in duration.
Any dog requiring drug discontinuation longer than 2 weeks was removed from the study.
More toceranib-treated dogs (n = 8) were removed from the study for therapy-associated
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Fig 1. Disease Free Interval. Kaplan-Meier disease-free interval (DFI) curves comparing dogs treated with toceranib to control dogs. Hash marks denote
censored observations; n = 63 toceranib-treated dogs; n = 63 control dogs. (A) Intent-to-treat analysis (p = 0.274). (B) Adherence analysis (p = 0.3).
doi:10.1371/journal.pone.0124889.g001
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adverse events compared to control dogs (n = 1). Seven dogs developed cyclophosphamide-in-
duced cystitis (n = 2 control; n = 5 toceranib-treated), resulting in replacement of cyclophos-
phamide with chlorambucil. Gastrointestinal adverse events in one toceranib-treated dog
resulted in a switch from cyclophosphamide to chlorambucil.
Gastrointestinal. Thirteen dogs experienced grade 1 vomiting while on toceranib, two of
which experienced more than one episode. One toceranib-treated dog developed grade 4 vom-
iting and diarrhea in conjunction with pancreatitis. The vomiting and diarrhea resolved with
supportive care and temporary drug discontinuation. Ten control dogs experienced grade 1
vomiting, with 3 dogs experiencing more than one episode. Seventeen toceranib-treated dogs
developed grade 1 diarrhea, with 12 dogs experiencing more than 1 episode. Sixteen dogs de-
veloped grade 2 diarrhea while on toceranib, with 6 dogs experiencing more than 1 episode.
Two toceranib-treated dogs developed grade 3 diarrhea, with one dog experiencing 3 episodes
of diarrhea. Both dogs with grade 3 diarrhea were removed from the study due to gastrointesti-
nal adverse events. Seven dogs not receiving toceranib developed grade 1 diarrhea, with one
Table 2. Median Disease Free Interval (DFI), Overall Survival (OS) and survival proportions by treatment group.
Outcome Survival Proportions
Analysis Group Median (days) 1 year 2 years 3 years
DFI ITT Toceranib 233 0.323 0.176 0.176
Toceranib (181, 338) (0.206, 0.447) (0.086, 0.292) (0.086, 0.292)
Control 215 0.259 0.131 0.065
Control (125, 288) (0.152, 0.378) (0.055, 0.241) (0.014, 0.175)
DFI A Toceranib 223 0.313 0.199 0.199
Toceranib (182, 338) (0.177, 0.459) (0.083, 0.351) (0.083, 0.351)
Control 198 0.278 0.183 0.091
Control (125, 296) (0.153, 0.418) (0.078, 0.323) (0.019, 0.235)
OS ITT Toceranib 318 0.384 0.163 0.082
Toceranib (250, 379) (0.263, 0.505) (0.082, 0.268) (0.024, 0.184)
Control 242 0.349 0.143 0.078
Control (197, 331) (0.235, 0.466) (0.070, 0.240) (0.025, 0.171)
Intervals reported are 95% conﬁdence intervals.
ITT = Intent to treat; A = Adherence
(N = 63 toceranib-treated dogs, 63 control dogs)
doi:10.1371/journal.pone.0124889.t002
Table 3. Hazard Ratios (HRs) and confidence intervals from Cox regression analysis.
Unadjusted Adjusteda
HR 95% CI p-value HR 95% CI p-value
DFI ITT 0.80 (0.54, 1.19) 0.274 0.80 (0.53, 1.20) 0.461
Adherence 0.79 (0.50, 1.23) 0.300 0.76 (0.48, 1.21) 0.252
OSb 1 year 1.01 (0.66, 1.54) 0.963 1.01 (0.64, 1.59) 0.961
2 years 1.40 (0.72, 2.75) 0.325 1.45 (0.70, 3.00) 0.316
aAdjusted for weight and gender (male, female).
bProportional hazards violated (p = 0.08 for OS ITT analysis, p<0.05 for all others).
ITT = Intent to treat
doi:10.1371/journal.pone.0124889.t003
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dog experiencing 2 episodes of diarrhea. Anorexia was generally mild and limited to grade 1
and 2 adverse events in both arms of the study.
Hematologic. Grade 1 neutropenia was the most common hematologic adverse event in
toceranib-treated dogs, with 14 dogs developing transient neutropenia. No dose adjustments or
temporary drug discontinuation were necessary due to transient low-grade hematologic toxici-
ty. Six dogs receiving toceranib, and 8 control dogs experienced grade 1 thrombocytopenia.
One dog experienced a grade 5 thrombocytopenia which occurred in the setting of widespread
metastatic disease.
Fig 2. Overall Survival. Kaplain-Meier overall survival (OS) curves comparing toceranib-treated dogs with control dogs. Hash marks denote censored
observations; n = 63 toceranib-treated dogs; n = 63 control dogs (p = 0.08).
doi:10.1371/journal.pone.0124889.g002
Table 4. Median disease free interval, median survival (in days) and Cox regression analysis of cancer location.
Analysis Location Median (days) 95% CI HR 95% CI p-value
DFI ITT Proximal Humerus 182 (127, 261) 1.28 (0.82, 2.01) 0.281
Other 233 (184, 296) - - -
DFI A Proximal Humerus 182 (124, 338) 1.17 (0.70, 1.94) 0.557
Other 224 (183, 309) - - -
OS ITT Proximal Humerus 243 (176, 309) 1.27 (0.82, 1.97) 0.280
Other 318 (242, 352) - - -
(N = 31 proximal humerus, 95 other locations)
ITT = Intent to treat; A = Adherence
doi:10.1371/journal.pone.0124889.t004
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Biochemical. The majority of elevations in liver transaminases were grade 1 and 2. Two
dogs receiving toceranib experienced grade 3 ALT elevations that resolved with a temporary
toceranib discontinuation and supportive care. One control dog experienced a grade 3 and 4
ALT and ALP elevation, respectively, which resolved with temporary discontinuation of
oral therapy.
Neuromuscular. Grade 1 and 2 weakness was seen in 4 toceranib-treated dogs and 3 con-
trol dogs. Two dogs receiving toceranib developed grade 3 weakness, with three separate epi-
sodes occurring in 1 dog. In both dogs, each episode resolved with a temporary toceranib
discontinuation. Low-grade musculoskeletal pain/lameness was noted in the absence of pro-
gressive disease in 8 toceranib-treated dogs and 5 control dogs.
Other. Other adverse events observed in dogs enrolled in this study included: elevated cre-
atinine kinase; otitis media; fever; urinary tract infection; epistaxis; stranguria; hyperglycemia;
hypoglycemia; indolent ocular ulcer; seizure; shaking/panting; skin erythema; pyoderma;
hyperkalemia; hypokalemia; hypoalbuminemia; hypercalcemia; ataxia; motor neuropathy; sen-
sory neuropathy. These adverse events were believed to be unrelated to toceranib/oral therapy,
and instead likely represent progression of disease or other co-morbid conditions.
Discussion
The benefits of amputation and adjuvant chemotherapy for dogs with OSA are well established
in veterinary medicine, however most dogs will succumb to metastatic disease within 1 year of
amputation and adjuvant chemotherapy, with 2 year survival rates reported in most studies of
only 10–15% [8,46]. Despite numerous attempts to improve outcome, little progress has been
made in extending survival for affected dogs. The purpose of this clinical trial was to determine
whether the addition of metronomic chemotherapy using piroxicam and cyclophosphamide
alone or in combination with toceranib would impact both disease free interval and overall sur-
vival in dogs with appendicular OSA following amputation and carboplatin chemotherapy. Re-
sults from this study demonstrate that piroxicam and cyclophosphamide metronomic therapy
with toceranib did not improve median DFI, median OS or the 1-year survival rate in dogs
with appendicular OSA over piroxicam and cyclophosphamide alone.
The median DFI and survival times reported here are similar to those reported for dogs that
receive carboplatin chemotherapy after amputation [3,7]. Furthermore, the 1-year survival
rates of 38.4% and 34.9% for toceranib-treated dogs and control dogs, respectively, are compa-
rable to the 35.4% 1-year survival rate reported for carboplatin alone. Analogous results have
been obtained with doxorubicin alone or in combination with carboplatin, cisplatin alone, and
carboplatin given concurrently with gemcitabine [5,8,47–49]. A recent retrospective study
compared multiple chemotherapy protocols used for canine appendicular OSA post-amputa-
tion. Differences in dose intensity and the chemotherapy protocol chosen did not significantly
influence the reported median DFI and OS of 291 days and 284 days, respectively [8]. These
data support the notion that alteration of therapeutic approaches to treat microscopic meta-
static disease using currently available cytotoxic chemotherapeutics is unlikely to result in sig-
nificant benefit for dogs with OSA.
Therapeutic approaches that target both the tumor itself as well as the tumor microenviron-
ment are increasingly recognized as important components in regulating the metastatic process
and several studies have investigated this approach. For example, studies in veterinary medi-
cine have reported on safety and efficacy of metronomic chemotherapy protocols in the treat-
ment of various tumors [9,10,50,51]. The combination of metronomic cyclophosphamide
(10 mg/m2) and piroxicam (0.3 mg/kg) was shown to be well-tolerated and suggests that met-
ronomic chemotherapy prolongs DFI for incompletely resected canine soft tissue sarcomas [9].
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The use of metronomic cyclophosphamide has been also shown to decrease the number of cir-
culating regulatory T-cells (Treg) and tumor microvessel density in tumor-bearing dogs when
cyclophosphamide was administered at 15 mg/m2/day [11]. Unfortunately, the doses and regi-
mens used in metronomic chemotherapy protocols are largely anecdotal, and predictive bio-
markers of clinical benefit in dogs with OSA have not been thoroughly evaluated. In the
present study cyclophosphamide and piroxicam were dosed at 10 mg/m2 and 0.3 mg/kg EOD,
respectively. This therapeutic regimen was established based on the available literature at the
beginning of the study, prior to demonstration of the immunomodulatory and antiangiogenic
effects of higher doses of cyclophosphamide. Given the reported immunomodulatory and anti-
angiogenic effects of cyclophosphamide used at higher doses, it is possible that the lower dose
of cyclophosphamide in the present study and the use of EOD dosing resulted in a treatment
regimen insufficient to significantly affect the tumor microenvironment, the number of circu-
lating Tregs, or both.
While biologic activity of toceranib in metastatic canine appendicular osteosarcoma has
been reported [37], the lack of improvement in DFI and OS in the present study suggests there
may be different molecular drivers at different stages of disease in canine OSA. It is possible
that while effects on tumor growth are observed in dogs with macroscopic metastatic pulmo-
nary lesions following toceranib therapy, microscopic lesions may become resistant to therapy
with in a short period of time, thereby negating any potential therapeutic value. Data generated
from several murine models have suggested that VEGF inhibitors modulate the tumor micro-
environment in a manner that can actually accelerate metastatic tumor growth [28,29,52].
There has therefore been concern that the use of VEGFR inhibitors in the setting of microscop-
ic disease could actually promote a more aggressive phenotype. Importantly, this study demon-
strated that the use of toceranib in dogs with microscopic metastatic OSA did not result in
shortened survival times or aberrant patterns of metastasis that would indicate the induction of
a more aggressive disease phenotype following treatment.
Recently, administration of toceranib at 2.75 mg/kg EOD to cancer-bearing dogs was associ-
ated with a significant decrease in circulating Tregs, possibly through indirect immunomodula-
tory mechanisms [39]. Doses of toceranib below the label dose (ranging from 2.4–2.9 mg/kg
EOD) still result in target inhibition, supporting the use of 2.75 mg/kg in the present study
[37]. Therefore, the lack of improvement in DFI and OS reported here is unlikely secondary to
the use of a lower dose of toceranib than the current label dose. Although VEGFR inhibition
was not specifically assessed in this study, upregulation of plasma VEGF concentrations follow-
ing toceranib treatment has been previously demonstrated in dogs receiving 2.4–2.9 mg/kg
EOD, consistent with effective VEGFR2 inhibition [37].
Adverse events necessitating administration of chlorambucil in place of cyclophosphamide
occurred in 8 dogs, with all but one of these due to sterile cystitis. The overall incidence of cy-
clophosphamide-induced cystitis is low in the veterinary literature, and increased risk has been
associated with a higher cumulative cyclophosphamide dose and higher dose intensity [53]. As
there were a small number of dogs in each group that developed cystitis (n = 2 control, n = 5
toceranib), and it is likely coincidence that a higher number of toceranib-treated dogs devel-
oped cystitis. The use of metronomic chlorambucil has been associated with some antitumor
activity in a variety of spontaneous canine tumors, and decreases in numbers of circulating
Tregs compared to baseline has been documented in dogs receiving chlorambucil [51]. While
the immunomodulatory effects of metronomic cyclophosphamide and chlorambucil have been
reported, the impact of chlorambucil administration in this study is not known. However,
given the small number of dogs that went on to receive this drug in place of cyclophosphamide,
it was unlikely to significantly impact outcome in either group.
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Multiple investigations have reported on the prognostic significance of OSA occurring in
the proximal humerus [3,7,54–57]. While decreased survival times were noted in dogs with tu-
mors located in the proximal humerus in the current study, the difference in OS was not signif-
icant compared to other tumor locations. This may have been due to the small number of dogs
that enrolled in the study with proximal humerus disease (n = 31). Alternatively, it is possible
that the metronomic therapy had an effect on outcome in this population to improve survival.
Future controlled studies would be necessary to determine the benefits of metronomic chemo-
therapy in this subset of patients.
Toceranib-treated dogs had a higher adverse event profile compared to control dogs, al-
though the adverse events reported were consistent with those expected based on prior pub-
lished studies. It is important to note that in the current study, dogs experiencing adverse
events while on toceranib were effectively managed with drug holidays, concomitant medica-
tions and/or dose reductions. The frequency of adverse events was lower than that reported in
a recent clinical trial of dogs with various solid tumors receiving toceranib at doses of 2.4–
2.9 mg/kg [37]. In this study, the adverse event profile was far superior to that associated with
the label dose of toceranib (3.25 mg/kg) but both adequate drug exposure and biologic activity
were maintained [37]. Despite the inherent difficulties in comparing findings from various
studies, the dose of toceranib utilized in the present study (2.75 mg/kg) was better tolerated
compared to the label dose, allowing improved adherence to the treatment protocol [36,37].
While necropsy was not required in the current study and the detection of metastatic disease
was largely dependent on clinical findings and thoracic radiographs, it is unlikely that gross
metastatic disease in other locations was missed in many dogs. The incidence of gross OSA me-
tastasis detectable with abdominal ultrasound has been previously reported, with abdominal
metastasis identified in 0–1.7% of dogs that do not have evidence of pulmonary metastatic dis-
ease [58,59]. Additionally, the reported rate for detecting unsuspected osseous metastasis with
nuclear scintigraphy in dogs with appendicular OSA at the time of initial presentation (prior to
amputation) is 7.8% [60]. Thus, while the lack of necropsy may have contributed to an under-
reporting of the true incidence of metastasis, thoracic radiography is considered a reliable diag-
nostic procedure to detect metastatic disease for most dogs following amputation and chemo-
therapy, with extrathoracic metastases usually identified by virtue of clinical signs (i.e.,
lameness for bone metastasis).
It is possible that the use of compounded therapeutics could have impacted our results. The
Apothecary Shoppe (now Avella Specialty Pharmacy) was chosen as the supplier of com-
pounded cyclophosphamide and piroxicam as this pharmacy is certified by the Pharmacy
Compounding Accreditation Board. However it is recognized that compounding may have re-
sulted in inadvertent overdosing or under dosing, resulting in increased toxicity or sub-thera-
peutic drug concentrations in some patients, respectively.
A potential weakness of the current study is that the metronomic treatment regimen began
after completion of carboplatin chemotherapy. This may have given the remaining microscopic
metastatic tumor cells time to develop resistance to multiple therapies, thus negating any im-
pact of the subsequent treatment. While the use of metronomic cyclophosphamide and piroxi-
cam administered concurrently with carboplatin for dogs with appendicular osteosarcoma was
reported to be well-tolerated in another study [50], no improvement in survival time was noted
with concurrent administration. Nevertheless, it may be warranted to determine if concurrent
use of toceranib in combination with metronomic chemotherapy and carboplatin significantly
impacts DFI and OS.
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Conclusions
The incorporation of toceranib into a commonly employed metronomic chemotherapy proto-
col failed to improve the DFI, OS and 1-year survival rates in dogs with appendicular OSA
after amputation and carboplatin chemotherapy compared to metronomic therapy alone. Fur-
thermore, the DFI, OS and 1-year survival rates in this study were similar to those previously
found when dogs with OSA undergo amputation and carboplatin chemotherapy treatment
alone. This study underscores the need for thorough interrogation of the molecular mecha-
nisms that drive tumor progression at various stages of disease so that novel approaches aimed
at optimizing activity against the tumor microenvironment can be successfully employed.
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